1
|
Tandavanitj R, Setthapramote C, De Lorenzo G, Sanchez-Velazquez R, Clark JJ, Rocchi M, McInnes C, Kohl A, Patel AH. Virus-like particles of louping ill virus elicit potent neutralizing antibodies targeting multimers of viral envelope protein. Vaccine 2024; 42:2429-2437. [PMID: 38458875 DOI: 10.1016/j.vaccine.2024.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Revised: 03/01/2024] [Accepted: 03/04/2024] [Indexed: 03/10/2024]
Abstract
Louping ill virus (LIV) is a tick-borne flavivirus that predominantly causes disease in livestock, especially sheep in the British Isles. A preventive vaccine, previously approved for veterinary use but now discontinued, was based on an inactivated whole virion that likely provided protection by induction of neutralizing antibodies recognizing the viral envelope (E) protein. A major disadvantage of the inactivated vaccine was the need for high containment facilities for the propagation of infectious virus, as mandated by the hazard group 3 status of the virus. This study aimed to develop high-efficacy non-infectious protein-based vaccine candidates. Specifically, soluble envelope protein (sE), and virus-like particles (VLPs), comprised of the precursor of membrane and envelope proteins, were generated, characterized, and studied for their immunogenicity in mice. Results showed that the VLPs induced more potent virus neutralizing response compared to sE, even though the total anti-envelope IgG content induced by the two antigens was similar. Depletion of anti-monomeric E protein antibodies from mouse immune sera suggested that the neutralizing antibodies elicited by the VLPs targeted epitopes spanning the highly organized structure of multimer of the E protein, whereas the antibody response induced by sE focused on E monomers. Thus, our results indicate that VLPs represent a promising LIV vaccine candidate.
Collapse
Affiliation(s)
- Rapeepat Tandavanitj
- MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom; Biologicals Research Group, Research and Development Institute, The Government Pharmaceutical Organization, Bangkok 10400, Thailand
| | - Chayanee Setthapramote
- MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom; Department of Clinical Pathology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok 10300, Thailand
| | - Giuditta De Lorenzo
- MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom
| | | | - Jordan J Clark
- MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom
| | - Mara Rocchi
- Moredun Research Institute, Midlothian EH26 0PZ, Scotland, United Kingdom
| | - Colin McInnes
- Moredun Research Institute, Midlothian EH26 0PZ, Scotland, United Kingdom
| | - Alain Kohl
- MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom; Departments of Vector Biology and Tropical Disease Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom
| | - Arvind H Patel
- MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom.
| |
Collapse
|
2
|
Volz A, Lim S, Kaserer M, Lülf A, Marr L, Jany S, Deeg CA, Pijlman GP, Koraka P, Osterhaus ADME, Martina BE, Sutter G. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens. Vaccine 2016; 34:1915-26. [PMID: 26939903 DOI: 10.1016/j.vaccine.2016.02.042] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2015] [Revised: 02/14/2016] [Accepted: 02/16/2016] [Indexed: 12/30/2022]
Abstract
West Nile virus (WNV) cycles between insects and wild birds, and is transmitted via mosquito vectors to horses and humans, potentially causing severe neuroinvasive disease. Modified Vaccinia virus Ankara (MVA) is an advanced viral vector for developing new recombinant vaccines against infectious diseases and cancer. Here, we generated and evaluated recombinant MVA candidate vaccines that deliver WNV envelope (E) antigens and fulfil all the requirements to proceed to clinical testing in humans. Infections of human and equine cell cultures with recombinant MVA demonstrated efficient synthesis and secretion of WNV envelope proteins in mammalian cells non-permissive for MVA replication. Prime-boost immunizations in BALB/c mice readily induced circulating serum antibodies binding to recombinant WNV E protein and neutralizing WNV in tissue culture infections. Vaccinations in HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice elicited WNV E-specific CD8+ T cell responses. Moreover, the MVA-WNV candidate vaccines protected C57BL/6 mice against lineage 1 and lineage 2 WNV infection and induced heterologous neutralizing antibodies. Thus, further studies are warranted to evaluate these recombinant MVA-WNV vaccines in other preclinical models and use them as candidate vaccine in humans.
Collapse
Affiliation(s)
- Asisa Volz
- German Centre for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Veterinaerstrasse 13, D-80539 Munich, Germany
| | - Stephanie Lim
- Viroscience Lab, Erasmus Medical Center, Rotterdam, The Netherlands; Artemis One Health Research Institute, Utrecht, The Netherlands
| | - Martina Kaserer
- German Centre for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Veterinaerstrasse 13, D-80539 Munich, Germany
| | - Anna Lülf
- German Centre for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Veterinaerstrasse 13, D-80539 Munich, Germany
| | - Lisa Marr
- German Centre for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Veterinaerstrasse 13, D-80539 Munich, Germany
| | - Sylvia Jany
- German Centre for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Veterinaerstrasse 13, D-80539 Munich, Germany
| | - Cornelia A Deeg
- Institute for Animal Physiology, LMU University of Munich, Munich, Germany
| | - Gorben P Pijlman
- Laboratory of Virology, Wageningen University, Wageningen, The Netherlands
| | - Penelope Koraka
- Viroscience Lab, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Albert D M E Osterhaus
- Viroscience Lab, Erasmus Medical Center, Rotterdam, The Netherlands; Artemis One Health Research Institute, Utrecht, The Netherlands
| | - Byron E Martina
- Viroscience Lab, Erasmus Medical Center, Rotterdam, The Netherlands; Artemis One Health Research Institute, Utrecht, The Netherlands
| | - Gerd Sutter
- German Centre for Infection Research (DZIF), Institute for Infectious Diseases and Zoonoses, LMU University of Munich, Veterinaerstrasse 13, D-80539 Munich, Germany.
| |
Collapse
|
3
|
Morris-Downes MM, Sheahan BJ, Fleeton MN, Liljeström P, Reid HW, Atkins GJ. A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model. Vaccine 2001; 19:3877-84. [PMID: 11427261 DOI: 10.1016/s0264-410x(01)00126-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
This study has examined the efficacy following intramuscular administration of a recombinant Semliki Forest virus (rSFV) vaccine, encoding the prME and NS1 proteins of louping ill virus (LIV), in sheep. Administration of rSFV-LIV vaccine resulted in transient detection at the injection site and draining lymph node only and no dissemination to distal sites. In addition, the recombinant vaccine offered complete protection against subcutaneous challenge with LIV, and partial protection following intranasal administration of LIV. Protected animals had no pathological changes normally associated with LIV infection, and had developed high antibody titres. In contrast, the two animals not protected exhibited classical clinical signs and neuropathological lesions of LIV infection. These findings indicate that rSFV-based vaccines have the potential to be developed as effective prototype vaccines for LIV.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/blood
- Base Sequence
- DNA Primers/genetics
- Encephalitis Viruses, Tick-Borne/genetics
- Encephalitis Viruses, Tick-Borne/immunology
- Encephalitis, Tick-Borne/immunology
- Encephalitis, Tick-Borne/pathology
- Encephalitis, Tick-Borne/prevention & control
- Encephalitis, Tick-Borne/veterinary
- Genetic Vectors
- Reverse Transcriptase Polymerase Chain Reaction
- Semliki forest virus/genetics
- Semliki forest virus/immunology
- Sheep
- Sheep Diseases/immunology
- Sheep Diseases/pathology
- Sheep Diseases/prevention & control
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/immunology
- Vaccines, Synthetic/pharmacology
- Viral Nonstructural Proteins/genetics
- Viral Nonstructural Proteins/immunology
- Viral Structural Proteins/genetics
- Viral Structural Proteins/immunology
- Viral Vaccines/genetics
- Viral Vaccines/immunology
- Viral Vaccines/pharmacology
Collapse
Affiliation(s)
- M M Morris-Downes
- Department of Microbiology, Moyne Institute of Preventive Medicine, Trinity College, Dublin 2, Ireland
| | | | | | | | | | | |
Collapse
|
4
|
Brinton MA, Kurane I, Mathew A, Zeng L, Shi PY, Rothman A, Ennis FA. Immune mediated and inherited defences against flaviviruses. CLINICAL AND DIAGNOSTIC VIROLOGY 1998; 10:129-39. [PMID: 9741638 DOI: 10.1016/s0928-0197(98)00039-7] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Flavivirus infection elicits an abundant immune response in the host which is directed against a number of the viral proteins. Resistance to flavivirus-induced disease can also be controlled via a non-immune mechanism involving the product of a naturally occurring murine gene, Flv. OBJECTIVES To review studies that have reported the mapping of epitopes on flavivirus proteins that elicit T- or B-cell immune responses in mice or humans and to discuss a possible mechanism for flavivirus-specific genetic resistance. STUDY DESIGN Purified viral proteins and synthetic peptides were used to map B-cell epitopes. Purified proteins, vaccinia-expressed viral protein fragments and synthetic peptides were used to map T-cell epitopes. Congenic-resistant, C3H/RV and congenic susceptible, C3H/He mice and cell cultures were used to study the mechanism of genetic resistance to flavivirus infection. RESULTS T- and B-cell epitopes have been mapped to the E, NS1 and NS3 proteins of several flaviviruses. Immune responses to the C, PreM, NS2a, NS4a, and NS5 proteins have also been documented. Data suggest that the Flv gene product acts intracellularly to suppress the synthesis of viral genomic RNA. CONCLUSIONS Although flavivirus infection elicits an abundant immune response, this response is not always rapid enough to protect the host from developing encephalitis. During secondary infections both the humoral and cellular flavivirus-specific responses can confer protection. Dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) appear to be caused by an overly vigorous immune response. In genetically resistant animals reduced production of virus results in a slower spread of the infection, which in turn allows time for the immune response to develop and to clear the infection before disease symptoms appear.
Collapse
Affiliation(s)
- M A Brinton
- Department of Biology, Georgia State University, Atlanta 30302-4010, USA.
| | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
The polymerase chain reaction (PCR) is a nucleic acid-based technique that enables the rapid and sensitive detection of specific micro-organisms. Although this technique is widely used in veterinary research, it has not yet found applications in routine microbiological analysis of veterinary clinical samples. However, advances in sample preparation together with the increasing availability of specific gene sequences will probably lead to the more widespread diagnostic use of PCR in the future. PCR is likely to have a strong impact in the epidemiology, treatment and prevention of animal infectious diseases.
Collapse
Affiliation(s)
- J M Rodriguez
- Departamento de Nutrición y Bromatología III, Facultad de Veterinaria, Universidad Complutense, Madrid, Spain
| |
Collapse
|
6
|
Allison SL, Stadler K, Mandl CW, Kunz C, Heinz FX. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J Virol 1995; 69:5816-20. [PMID: 7637027 PMCID: PMC189449 DOI: 10.1128/jvi.69.9.5816-5820.1995] [Citation(s) in RCA: 178] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
A quantitative study was performed to investigate the requirements for secretion of recombinant soluble and particulate forms of the envelope glycoprotein E of tick-borne encephalitis (TBE) virus. Full-length E and a carboxy terminally truncated anchor-free form were expressed in COS cells in the presence and absence of prM, the precursor of the viral membrane protein M. Formation of a heteromeric complex with prM was found to be necessary for efficient secretion of both forms of E, whereas only low levels of anchor-free E were secreted in the absence of prM. The prM-mediated transport function could also be provided by coexpression of prM and E from separate constructs, but a prM-to-E ratio of greater than 1:1 did not further enhance secretion. Full-length E formed stable intracellular heterodimers with prM and was secreted as a subviral particle, whereas anchor-free E was not associated with particles and formed a less stable complex with prM, suggesting that prM interacts with both the ectodomain and anchor region of E.
Collapse
Affiliation(s)
- S L Allison
- Institute of Virology, University of Vienna, Austria
| | | | | | | | | |
Collapse
|
7
|
Venugopal K, Jiang WR, Gould EA. Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins. Vaccine 1995; 13:1000-5. [PMID: 8525682 DOI: 10.1016/0264-410x(95)00015-s] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
St. Louis encephalitis (SLE) is an important mosquito-borne disease of great public health concern in parts of the United States. South America and Canada. Protective immunogens of flaviviruses produced in different expression systems have been shown to be effective against virulent virus infection in laboratory animal models. Here we show that the pre-membrane and envelope (PrM/E) of SLE virus expressed in insect and mammalian cell systems using baculovirus and vaccinia virus, respectively, are processed correctly and showed similar antigenic characteristics as the authentic proteins. Immunization with the recombinant proteins individually or in combination resulted in neutralizing and protective immune responses. A schedule consisting of initial immunization with recombinant vaccinia virus followed by a secondary boost with recombinant baculovirus protein resulted in higher levels of neutralizing and protective immune responses. The advantages of the use of such a combined approach as a general immunization strategy are discussed.
Collapse
Affiliation(s)
- K Venugopal
- Institute of Virology and Environmental Microbiology, Oxford, UK
| | | | | |
Collapse
|
8
|
Abstract
Flavivirus diseases have caused great public health concern for over three centuries, with diseases like yellow fever, dengue, Japanese encephalitis and tick-borne encephalitis causing thousands of deaths. Although yellow fever epidemics can be brought under control by the use of vaccine or mosquito-control measures, there have been many examples of its re-emergence as an epidemic disease. Similarly, the use of vaccines or arthropod-control measures have failed to prevent the spread of other flaviviruses such as Japanese encephalitis virus. There has been rapid growth in the knowledge of molecular information on flaviviruses in the last decade, and on the basis of this information several potential recombinant subunit vaccines are being developed and appear to be effective experimentally. Moreover, the assumption that humoral immunity induced by virus structural envelope glycoproteins is the only effective means of providing protection against flavivirus infection can be questioned. This review attempts to summarize recent thinking in this field and to evaluate the different systems available as potential future flavivirus vaccines in inducing protective immunity.
Collapse
Affiliation(s)
- K Venugopal
- Institute of Virology and Environmental Microbiology, Oxford, UK
| | | |
Collapse
|